Variables | Rituximab group, n = 34 | IV-CY group, n = 20 | p value |
---|---|---|---|
All adverse events, no. | 19 | 14 | 0.39 |
Death, no | 4 | 4 | 0.45 |
Sepsis (pyelonephritis) | Bacterial pneumonia | ||
Invasive pulmonary aspergillosis | PCP + invasive pulmonary aspergillosis | ||
Bacterial pneumonia | Invasive pulmonary aspergillosis | ||
Stroke | Sepsis (bacterial pneumonia) | ||
Leukopenia, no | 4 | 4 | 0.45 |
Thrombocytopenia, no | 4 | 2 | 1.00 |
Severe infection, no | 11 | 12 | 0.09 |
CMV infection, n = 2 | PCP | ||
Bacterial pneumonia, n = 2 | CMV infection, n = 2 | ||
Legionella pneumonia | Acute cholangitis | ||
Sepsis (pyelonephritis) | Tuberculosis | ||
Invasive pulmonary aspergillosis | PCP + invasive pulmonary aspergillosis | ||
PCP | Bacterial pneumonia, n = 4 | ||
Invasive pulmonary aspergillosis | |||
Sepsis (bacterial pneumonia) | |||
VTE, no | 1 | 0 | 0.37 |